Study on the anti-colorectal cancer efficacy of the paclitaxel/oxaliplatin co-delivery system
A biotin-modified polyethylene glycol–paclitaxel nanocarrier was developed for the co-delivery of paclitaxel and oxaliplatin in colorectal cancer therapy. The biotin–PEG–PTX copolymer was synthesized and characterized by FTIR spectroscopy, and paclitaxel nanoparticles and oxaliplatin-loaded nanoparticles were prepared through self-assembly. Their physicochemical properties, stability, morphology, and drug-release behavior were evaluated using DLS, TEM, and in vitro release assays. OXA@PTX nanoparticles inhibited HCT-116 cell growth, showed combination-associated cytotoxicity and time-dependent nanoparticle-associated fluorescence, and produced lower macrophage-associated fluorescence than free FITC under the tested conditions. In tumor-bearing mice, the formulation showed qualitatively greater tumor-associated fluorescence, reduced Ki-67 expression, and increased TUNEL staining, with no obvious histopathological abnormalities in major organs. The nanocarrier also exhibited sustained, pH-dependent drug release, supporting its potential as a biotin-functionalized platform for paclitaxel and oxaliplatin co-delivery in colorectal cancer therapy.
Authors
- Chunlian He (ORCID: https://orcid.org/0000-0001-9576-8343)
- Qinyan Xie
- Ruiyi Tan
- Ziqin Zeng
- Yangfen Fu
- Lewei Li (ORCID: https://orcid.org/0009-0003-9590-1994)
- Hao Deng
- Xiuteng Cao
- Benjie Zhang
- Yuxin Li
- Jiaxin Yin
- Song Chen
Publication Details
- Journal
- Figshare
- Published
- 2026-11-19
- DOI
- https://doi.org/10.6084/m9.figshare.35061611
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00